0001638599-18-001327.txt : 20181206
0001638599-18-001327.hdr.sgml : 20181206
20181206060127
ACCESSION NUMBER: 0001638599-18-001327
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181204
FILED AS OF DATE: 20181206
DATE AS OF CHANGE: 20181206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Mahesh V.
CENTRAL INDEX KEY: 0001579872
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36357
FILM NUMBER: 181218610
MAIL ADDRESS:
STREET 1: C/O LIPOCINE, INC.
STREET 2: 675 ARAPEEN DRIVE, STE. 202
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lipocine Inc.
CENTRAL INDEX KEY: 0001535955
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 990370688
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 ARAPEEN DRIVE, SUITE 202
CITY: SALT LAKE CITY
STATE: X1
ZIP: 84108
BUSINESS PHONE: 801 994 7383
MAIL ADDRESS:
STREET 1: 675 ARAPEEN DRIVE, SUITE 202
CITY: SALT LAKE CITY
STATE: X1
ZIP: 84108
FORMER COMPANY:
FORMER CONFORMED NAME: MARATHON BAR CORP
DATE OF NAME CHANGE: 20111130
4
1
doc4_5817.xml
PRIMARY DOCUMENT
X0306
4
2018-12-04
0
0001535955
Lipocine Inc.
LPCN
0001579872
Patel Mahesh V.
675 ARAPEEN DRIVE
SUITE 202
SALT LAKE CITY
UT
84010
1
1
0
0
President and CEO
Restricted stock unit
0
2018-12-04
4
A
0
290000
0
A
2019-12-04
2028-12-04
Common Stock
290000
290000
D
Stock Option (Right to Buy)
1.46
2018-12-04
4
A
0
150000
1.46
A
2019-12-04
2028-12-04
Common Stock
150000
150000
D
Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit
Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020.
Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 4, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.
/s/Mahesh Patel
2018-12-05